Site Editor

William J. Gradishar, MD, FACP, FASCO

Advertisement
Advertisement

Natália Polidorio, MD, PhD, on the Impact of Race on Therapeutic Outcomes in Triple-Negative Breast Cancer

Posted: Friday, April 5, 2024

Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses study findings that may potentially affect treatment decision-making for patients with early-stage triple-negative breast cancer, depending on their race and possibly other factors, as well as whether they receive neoadjuvant chemoimmunotherapy or chemotherapy alone.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.